← Leaderboards
Pratiti Bandopadhayay
Dana-Farber Cancer Inst
$2,988,759
Attributed
$2,988,759
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $403.6K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,988,759 · 3
By mechanism
R37$1,989,782 · 1
R00$696,899 · 1
K99$302,078 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Rameen Beroukhim$9,639,646
- Daphne A. Haas-Kogan$5,585,485
- Franziska Michor$16,040,992
- Tracy T Batchelor$27,819,477
- Kent W Mouw$5,412,243
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroPik3ca GeneIn VivoMalignant NeoplasmsResponseWhole GenomeDiagnosisMutationIn Vivo ModelOncogenicProteinsRecurrenceSignal TransductionTumorCellsChildPathway InteractionsInsightExperimental StudyOncogenesGenesInhibitor/AntagonistCancer BiologyBromodomain
Grant awards (10)
Targeting vulnerabilities of PPM1D-mutant gliomas$403,607
R37 · FY2025 · CA · contact PI
Targeting vulnerabilities of PPM1D-mutant gliomas$383,426
R37 · FY2024 · CA · contact PI
Targeting vulnerabilities of PPM1D-mutant gliomas$395,535
R37 · FY2023 · CA · contact PI
Targeting vulnerabilities of PPM1D-mutant gliomas$403,607
R37 · FY2022 · CA · contact PI
Targeting vulnerabilities of PPM1D-mutant gliomas$403,607
R37 · FY2021 · CA · contact PI
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma$249,000
R00 · FY2020 · CA · contact PI
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma$198,899
R00 · FY2019 · CA · contact PI
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma$249,000
R00 · FY2018 · CA · contact PI
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma$151,039
K99 · FY2017 · CA · contact PI
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma$151,039
K99 · FY2016 · CA · contact PI